Table 1. Priority discussion and research questions.

Prioritized Discussions	Priority Research Questions
Vaccines and novel vector-targeted vaccinology	How does pathogen diversity contribute to the success of vaccine and/or therapeutic candidates? Is there a role for vector saliva in risk assessments, prophylactics against vector exposure, or diagnostics? How can we leverage continued understanding of the bite-site microenvironmental changes due to vector saliva to aid in development of therapeutics, likely using controlled human infection models? What are the diagnostic needs to accurately surveil and detect outbreaks of VBD in endemic versus epidemic and/or emergent situations?
Exposure risk and transmission	What is the contribution of asymptomatic and subclinical infections to the overall transmission? What factors govern the heterogeneity in asymptomatic and/or subclinical rates? How can vector control programs best engage the community as partners for control success as well as to educate for exposure awareness and mitigation? What extrinsic or intrinsic factors govern exposure risk and how do those factors themselves change in the face of anthropogenic pressures? What is the current and future roles of alternative vectors? What is the potential for secondary vectors to adapt and thus increase their public health relevance?
Eco-environmental drivers of transmission	How will continued urbanization and land-use changes affect the distribution and relative importance of vector populations? What are the microenvironmental effects of climate change with respect to vector–pathogen interactions that define transmission potential? What is the role of biodiversity in shaping transmission both in endemic and epidemic scenarios? How can basic VBD and vector research be integrated into future development plans to meet the needs of growing populations but still mitigate disease risk?